API | rotavirus vaccine, live, oral, tetravalent

rotavirus vaccine, live, oral, tetravalent (RotaShield) Report issue

Vaccine Approved ^FDA

AACT

Active Ingredient History

NOW

Rotavirus vaccine is a vaccine used to protect against rotavirus infections, which are the leading cause of severe diarrhea among young children. The vaccines prevent 15–34% of severe diarrhea in the developing world and 37–96% of severe the risk of death among young children due to diarrhea. Immunizing babies decreases rates of disease among older people and those who have not been immunized. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules: Missing data

More Chemistry

Pharmacology

Mechanisms of Action: Missing data
Multi-specific: Missing data
Black Box: Missing data
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: Missing data

live attenuated tetravalent (g1-g4) bovine-human reassortant rotavirus vaccine | rotashield | rotavirus serotype 1 reassortant, rotavirus serotype 2 reassortant, rotavirus serotype 3 rhesus, rotavirus serotype 4 reassortant | rotavirus serotype g1, serotype g2, serotype g3, serotype g4, serotype p1 | rotavirus vaccine, live, oral, tetravalent

Organizations (2)

Research & Development (2)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (1)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (1)

Rotavirus Infections (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 3
# of Trial Organizations: 2

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue